CPA
PBYI icon

Capital Performance Advisors’s Puma Biotechnology PBYI Stock Holding History

Capital Performance Advisors’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-15
Closed -$38 – 1937
2024
Q3 		$38 Buy
+15
New +$45 ﹤0.01% 2819

Other funds holding PBYI

ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Capital Performance Advisors's PBYI Position: Q4 2024 in Review

Capital Performance Advisors sold out of Puma Biotechnology (PBYI) in Q4 2024, closing a stake of 15 shares — an estimated $38 sold.

Capital Performance Advisors first reported a position in PBYI in Q3 2024 and held it in 1 quarter. The position peaked at $38 in Q3 2024. 112 funds tracked by Wall St. Rank hold PBYI as of Q4 2024.

  • Capital Performance Advisors reported no remaining Puma Biotechnology position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 15 Puma Biotechnology shares in Q4 2024, an estimated $38.
  • Capital Performance Advisors first reported a position in Puma Biotechnology in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Puma Biotechnology position peaked at $38 in Q3 2024.
  • 112 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.